The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics
  • Acronyms SUMAVA
  • Most Recent Events

    • 08 Oct 2015 Results published in the British Journal of Clinical Pharmacology
    • 10 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 01 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top